Follow
Mariano Provencio
Mariano Provencio
Hospital Universitario Puerta de Hierro. Universidad Autónoma de Madrid.
Verified email at salud.madrid.org
Title
Cited by
Cited by
Year
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre …
R Rosell, E Carcereny, R Gervais, A Vergnenegre, B Massuti, E Felip, ...
The lancet oncology 13 (3), 239-246, 2012
62942012
Screening for epidermal growth factor receptor mutations in lung cancer
R Rosell, T Moran, C Queralt, R Porta, F Cardenal, C Camps, M Majem, ...
New England Journal of Medicine 361 (10), 958-967, 2009
29592009
Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer
PM Forde, J Spicer, S Lu, M Provencio, T Mitsudomi, MM Awad, E Felip, ...
New England Journal of Medicine 386 (21), 1973-1985, 2022
12502022
Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non–small-cell lung cancer
M Cobo, D Isla, B Massuti, A Montes, JM Sanchez, M Provencio, ...
Journal of clinical oncology 25 (19), 2747-2754, 2007
6642007
Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial
M Provencio, E Nadal, A Insa, MR García-Campelo, J Casal-Rubio, ...
The Lancet Oncology 21 (11), 1413-1422, 2020
6222020
Patterns of outcome and prognostic factors in primary large cell lymphoma of the testis in a survey of 373 patients by the International Extranodal Lymphoma Study Grfoup (IELSG).
E Zucca, A Conconi, TI Mughal, AH Sarris, JF Seymour, U Vitolo, R Klasa, ...
Journal of Clinical Oncology 21, 20-27, 2003
5682003
Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients
R Rosell, KD Danenberg, V Alberola, G Bepler, JJ Sanchez, C Camps, ...
Clinical Cancer Research 10 (4), 1318-1325, 2004
5532004
Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non–small-cell lung cancer patients with EGFR mutations
R Rosell, MA Molina, C Costa, S Simonetti, A Gimenez-Capitan, ...
Clinical Cancer Research 17 (5), 1160-1168, 2011
3582011
Presence of tumor DNA in plasma of breast cancer patients: clinicopathological correlations
JM Silva, G Dominguez, JM Garcia, R Gonzalez, MJ Villanueva, ...
Cancer research 59 (13), 3251-3256, 1999
3581999
Vesicle-related microRNAs in plasma of nonsmall cell lung cancer patients and correlation with survival
J Silva, V García, A Zaballos, M Provencio, L Lombardía, L Almonacid, ...
European Respiratory Journal 37 (3), 617-623, 2011
3292011
Promoter methylation of the PTEN gene is a common molecular change in breast cancer
JM García, J Silva, C Peña, V Garcia, R Rodríguez, MA Cruz, B Cantos, ...
Genes, Chromosomes and Cancer 41 (2), 117-124, 2004
3092004
Cancer‐associated fibroblast and M 2 macrophage markers together predict outcome in colorectal cancer patients
M Herrera, A Herrera, G Domínguez, J Silva, V García, JM García, ...
Cancer science 104 (4), 437-444, 2013
3012013
IASLC multidisciplinary recommendations for pathologic assessment of lung cancer resection specimens after neoadjuvant therapy
WD Travis, S Dacic, I Wistuba, L Sholl, P Adusumilli, L Bubendorf, P Bunn, ...
Journal of Thoracic Oncology 15 (5), 709-740, 2020
2712020
Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non–small-cell lung cancer: A Spanish Lung Cancer Group phase III …
V Alberola, C Camps, M Provencio, D Isla, R Rosell, C Vadell, I Bover, ...
Journal of clinical oncology 21 (17), 3207-3213, 2003
2712003
Cancer antigen 125 associated with multiple benign and malignant pathologies
C Miralles, M Orea, P Espana, M Provencio, A Sánchez, B Cantos, ...
Annals of Surgical Oncology 10, 150-154, 2003
2552003
Genetic variants associated with cancer therapy–induced cardiomyopathy
P Garcia-Pavia, Y Kim, MA Restrepo-Cordoba, IG Lunde, H Wakimoto, ...
Circulation 140 (1), 31-41, 2019
2462019
A prospective phase II trial of erlotinib in advanced non-small cell lung cancer (NSCLC) patients (p) with mutations in the tyrosine kinase (TK) domain of the epidermal growth …
L Paz-Ares, JM Sanchez, A Garcia-Velasco, B Massuti, G Lopez-Vivanco, ...
Journal of Clinical Oncology 24 (18_suppl), 7020-7020, 2006
2392006
Customized treatment in non-small-cell lung cancer based on EGFR mutations and BRCA1 mRNA expression
R Rosell, L Perez-Roca, JJ Sanchez, M Cobo, T Moran, I Chaib, ...
PloS one 4 (5), e5133, 2009
2372009
PLCG1 mutations in cutaneous T-cell lymphomas
JP Vaqué, G Gómez-López, V Monsálvez, I Varela, N Martínez, C Pérez, ...
Blood, The Journal of the American Society of Hematology 123 (13), 2034-2043, 2014
2322014
First-line nivolumab plus ipilimumab in advanced NSCLC: 4-year outcomes from the randomized, open-label, phase 3 CheckMate 227 part 1 trial
LG Paz-Ares, SS Ramalingam, TE Ciuleanu, JS Lee, L Urban, RB Caro, ...
Journal of Thoracic Oncology 17 (2), 289-308, 2022
2312022
The system can't perform the operation now. Try again later.
Articles 1–20